ALKS - Alkermes PLC Debt to Book Capitalization Ratio

Graphic logo of Alkermes PLC (ALKS)

Alkermes plc (ALKS) generates revenue from the sale of treatments for addiction and schizophrenia, while the spin-off of its oncology division and breakthroughs in narcolepsy therapy drive growth, which currently stands at 0.92. Complex injection patents and stringent FDA oversight serve as a moat for the business. This price action chart on GURU.Markets illustrates asset dynamics within the CNS drug ecosystem.

ALKS (Alkermes Corp) Debt to Book Value history from 07/04/2022 to 10/27/2026

Alkermes PLC (ALKS) - metric breakdowns and financial figures

- price and consensus price forecast:
Stock Price Alkermes plc|ALKS - Analyst Consensus Forecast
- market capitalization data:
Market Value Alkermes Corp|ALKS - Value Adjusted for Debt and Cash
- book capitalization data:
Net Assets per Single Share Alkermes|ALKS - Company Net Assets|Market Capitalization to Book Value Ratio alkermes.com|ALKS - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Alkermes plc|ALKS - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Alkermes Inc.|ALKS - Company Aggregate Indebtedness|Debt to Book Capitalization Ratio Alkermes Corp
Summary company analytics:Alkermes plc
Core merchandise of Alkermes Inc.

For Alkermes plc (ALKS), whose expenditures on multi-year clinical trials for psychotropic agents are colossal, the total debt-to-book capitalization ratio reflects the balance between leverage and equity. A decrease in this ratio confirms financial autonomy and the absence of default risk, whereas excessive conservatism in borrowing may limit the pace of development for innovative drug delivery systems.

Competitors of Alkermes plc (ALKS)

Debts to Book Capitalization AVDL (Avadel Pharmaceuticals)|atai.life - Debts to Book Capitalization|Debt to Book Capitalization Ratio GH Research (GHRS)|MNMD: Debt to Net Assets Ratio|CMPS (Compass Pathways) - Debt to Book Capitalization Ratio|LB Corp (LBRX) - Debt to Book Value|DRUG (Bright Minds Biosciences) - Debts to Book Capitalization|Debts to Book Capitalization vandapharma.com (VNDA)|Cybin Inc. (CYBN) - Debt to Book Value|Debt to Net Assets Ratio ANRO (Alto Neuroscience Inc)|NRx Pharma (NRXP) - Debt to Book Capitalization Ratio|Cingulate Inc - Debts to Book Capitalization Ratio|Debt to Book Capitalization Ratio SILO (Silo Pharma, Inc.)|China Pharma Holdings (CPHI) - Debts to Net Assets|Debt to Book Value CMND|Psyence Biomedical Ltd (PBM) - Debts to Book Value|Debts to Book Capitalization SPRC|Debt to Book Value Seelos Therapeutics Inc|Virpax Pharmaceuticals (VRPX) - Debts to Book Capitalization|Debt to Net Assets Ratio KRTX (karunatx.com)